Attenuation of inflammatory polyarthritis in TNF transgenic mice by diacerein: comparative analysis with dexamethasone, methotrexate and anti-TNF protocols

Table 1 Semiquantitative clinical assessment based on arthritis scores of ankle joints in experimental Tg197 mice

		% of total joints
Treatment	Joints scored	AS ≤ 1	AS > 1	Mean AS ± standard error
Untreated	20	25	75	1.40 ± 0.07
WFI	20	35	65	1.35 ± 0.06
Diacerein 2 mg/kg daily	18	89	11	0.97 ± 0.06*
Diacerein 20 mg/kg daily	16	69	31	1.00 ± 0.11*
Diacerein 60 mg/kg daily	20	85	15	0.88 ± 0.08*
Methotrexate 1 mg/kg three times weekly	12	50	50	1.33 ± 0.16
Dexamethasone 0.5 mg/kg daily	12	100	0	0.75 ± 0.11*
CB0006 5 mg/kg weekly	12	100	0	0*

Both ankle joints of experimental Tg197 mice were subjected to clinical assessment at 7 weeks of age. In the case of the methotrexate, dexamethasone, and anti-tumor necrosis factor antibody treatments (CB0006), the data shown are derived from one representative from three independent experiments. *P < 0.05 versus untreated or water for injection (WFI) treated Tg197 control groups. AS, arthritis score.

ISSN: 1478-6362